Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy
- 1 January 2015
- journal article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 25 (1) , 96-105
Abstract
No abstract availableKeywords
Funding Information
- Muscular Dystrophy Campaign
- Parent Project Muscular Dystrophy
- United Parent Projects Muscular Dystrophy
- AFM Telethon
- BMBS COST Action BM1207
This publication has 43 references indexed in Scilit:
- The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseasesOrphanet Journal of Rare Diseases, 2013
- The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and AcademiaHuman Mutation, 2013
- Enhancing translation: Guidelines for standard pre-clinical experiments in mdx miceNeuromuscular Disorders, 2012
- The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: Report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009Neuromuscular Disorders, 2010
- Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary careThe Lancet Neurology, 2010
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial managementThe Lancet Neurology, 2010
- Standards of Care for Duchenne Muscular Dystrophy: Brief Treat-NMD Recommendations2009
- Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on “Pre-clinical testing for Duchenne dystrophy”: Washington DC, October 27th–28th 2007 and Zürich, June 30th-July 1st 2008Neuromuscular Disorders, 2009
- Mammalian animal models for Duchenne muscular dystrophyNeuromuscular Disorders, 2009
- ATS Statement: Guidelines for the Six-Minute Walk TestAmerican Journal of Respiratory and Critical Care Medicine, 2002